One of the leading experimental vaccines for Covid-19 in the world seems to work in young people and the elderly.
The University of Oxford and its trading partner, AstraZeneca, will not publish data from early vaccine trials, as they will be evaluated by other colleagues, but AstraZeneca confirmed key findings about the vaccine at a closed academic meeting. . The vaccine is called AZD1222.
Phase II evidence has shown that people over the age of 56 - and some over the age of 70 - produced the same antibody response as younger volunteers. The data also show that fewer side effects were reported in the elderly, which is encouraging.
A working vaccine is seen as an important factor in the battle against Covid-19. Even if the vaccines are not completely protective, they can reduce the severity of the disease by causing people to avoid hospitalization.
It should be noted, however, that the AZD1222 is not expected to be available until 2021. The potential delivery is projected in the first half of 2021. AstraZeneca is committed to mass production and has a capacity of 3 billion doses.
Source: Guardian
